{
  "drug_status": {
    "Lucicebtide": "success"
  },
  "extractions": {
    "Lucicebtide": {
      "drug_name": "Lucicebtide",
      "drug_classes": [
        "C/EBPβ Antagonist",
        "Immunomodulator"
      ],
      "selected_sources": [
        "abstract_title",
        "https://pubmed.ncbi.nlm.nih.gov/40103809/",
        "https://www.prnewswire.com/news-releases/sapience-therapeutics-provides-data-update-from-phase-2-trial-of-lucicebtide-in-patients-with-glioblastoma-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-302470177.html"
      ],
      "confidence_score": 1.0,
      "extraction_details": [
        {
          "extracted_text": "antagonism of C/EBPβ",
          "normalized_form": "C/EBPβ Antagonist",
          "class_type": "MoA",
          "evidence": "Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition",
          "source": "abstract_title",
          "rules_applied": [
            "Rule 1: Prioritize abstract title",
            "Rule 3: Apply Title Case",
            "Rule 11: Include biological target",
            "Rule 15: Capture Antagonist with target"
          ]
        },
        {
          "extracted_text": "immunomodulator",
          "normalized_form": "Immunomodulator",
          "class_type": "Therapeutic",
          "evidence": "These results identify lucicebtide as a novel immunomodulator that reprograms immunosuppressive macrophage populations",
          "source": "https://pubmed.ncbi.nlm.nih.gov/40103809/",
          "rules_applied": [
            "Rule 3: Apply Title Case",
            "Rule 5: Singular form"
          ]
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "The abstract title explicitly identifies the drug as an antagonist of C/EBPβ. Search results confirm this mechanism and also classify the drug as an immunomodulator due to its role in reprogramming macrophage populations.",
      "success": true
    }
  }
}